CJC-1295 (no DAC) 5 mg + Ipamorelin 5 mg

Research Blend

CJC-1295 (no DAC) 5 mg + Ipamorelin 5 mg

$35.00

In stock

Research identity: two-component GH-axis blend labeled 5 mg CJC-1295 (no DAC) plus 5 mg Ipamorelin.

  • Component-level human PK/PD records
  • With-DAC versus no-DAC evidence distinction
  • Exact-blend limitations, identity checks, and primary sources below

Catalog scope: 5 mg + 5 mg states the listed blend composition; it is not a dose, schedule, or use instruction. Component studies do not prove outcomes for this exact blend. For laboratory research only; not for human or veterinary use.

COMPOUND DOSSIER Read identity, mechanism, evidence, limits, and sources
Catalog sourceResearch Here
Request methodEmail review
Research recordFull dossier below

BUILD ONE COMPLETE LIST

Need more than one item?

Add this item, keep browsing, and add every product or option you need. Your list stays saved in this browser until you send one complete email request or remove it.

  1. 1Choose an in-stock or available-for-request option and quantity.
  2. 2Add it to your request list and continue shopping.
  3. 3Review the full list and send one email request.

RESEARCH HERE · COMPOUND DOSSIER

The record behind the shelf.

Plain-language identity, mechanism, evidence maturity, study endpoints, limitations, and direct source records—organized for careful reading, never copied from a dosing site.

COMPONENT-LEVEL HUMAN PK/PDBLEND EVIDENCE LIMITED

TWO-PATHWAY GH-AXIS BLEND

CJC-1295 (no DAC) + Ipamorelin

A two-component catalog blend intended to pair a GHRH-pathway ligand with a ghrelin-receptor secretagogue. The useful literature is mostly component-specific; it should not be presented as proof for this exact 5 mg + 5 mg blend.

GHRHR CONTEXTGHS-R1aGH / IGF-I READOUTS
Catalog ratio
5 mg + 5 mg · 10 mg total
Evidence structure
Component PK/PD + preclinical pharmacology
Critical naming issue
“No DAC” must not be confused with long-acting CJC-1295
Exact-blend evidence
No controlled efficacy record indexed here

01

What the pairing represents

GHRH-receptor and ghrelin-receptor signaling are distinct research pathways that converge on growth-hormone release. A blend may be studied as a combined system, but component findings cannot automatically establish blend-level performance.

02

What researchers measured

  • Plasma concentration and pharmacokinetic behavior
  • Growth-hormone and IGF-I response curves
  • Receptor selectivity in pharmacology models
  • Time-linked endocrine markers under controlled observation

03

What the record does not prove

  • That with-DAC CJC-1295 data apply to a no-DAC label
  • That separate component studies establish this blend's efficacy
  • That a 1:1 stated mass confirms identity or equimolar activity
  • That endocrine PK/PD establishes a health or performance outcome

EVIDENCE SNAPSHOT

The distinction that most product pages miss.

The human CJC-1295 record below studied a long-acting drug-affinity-complex construct. That is not automatically the same material as a product labeled “CJC-1295 no DAC.”

2006 · HUMAN STUDYLong-acting CJC-1295 PK/PD

Randomized, placebo-controlled human record measuring GH and IGF-I after a DAC-containing construct.

PMID 16352683 ↗ 1999 · HUMAN PK/PDIpamorelin in healthy volunteers

Dose-escalation modeling of plasma ipamorelin and growth-hormone responses in healthy male volunteers.

PMID 10496658 ↗ 1998 · PHARMACOLOGYIpamorelin selectivity characterization

Foundational receptor/pharmacology record describing selectivity for growth-hormone release.

PMID 9849822 ↗

DETAILED COMPOUND GUIDE

What the blend claims—and what the evidence actually covers.

The commercial pages make this blend sound settled. The research record is more complicated because “CJC-1295 no DAC,” CJC-1295 with DAC, Ipamorelin, and the exact 1:1 blend are different evidence objects.

01Reported research findings+

A 2006 randomized human study found sustained GH and IGF-I responses after long-acting CJC-1295 with a drug-affinity complex. That record does not automatically describe material labeled “CJC-1295 no DAC.”

A separate 1999 human study modeled Ipamorelin pharmacokinetics and GH response in healthy male volunteers. It found dose-proportional exposure, an approximately two-hour terminal half-life, and a single time-linked GH-release episode.

No controlled human efficacy study for this exact 5 mg + 5 mg premixed blend is indexed here.

02Purported benefits versus evidence+

Commercial guide sites commonly claim improved GH pulses, lean-mass support, fat oxidation, recovery, sleep, skin changes, and minimal cortisol or prolactin effects.

The component literature supports GH-axis pharmacology and selected PK/PD observations. It does not establish all of those wellness, body-composition, sleep, or recovery outcomes for this exact blend.

03Side effects and uncertainty+

Commercial pages commonly list injection-site reactions, transient flushing, headache, water retention, tingling, fatigue, or appetite changes. The available human studies are small, component-specific, and not designed to establish long-term safety for this blend.

An absence of serious adverse events in a short component study is not proof of long-term blend safety, purity, sterility, or suitability.

04Contraindications and interactions+

There is no FDA-approved contraindication or interaction label for this CJC-1295 (no DAC) + Ipamorelin research blend.

Internet contraindication lists often mention active malignancy, pregnancy, glucose-regulation problems, pituitary or endocrine disorders, and concurrent GH-axis agents. These should not be presented as a validated complete label. No controlled interaction study for the exact blend was found.

05Protocol and handling context+

Commercial sites publish bacteriostatic-water volumes, syringe-unit charts, timing, cycling, and “maximum protocols.” Those tables are not validated by a controlled efficacy study of this exact catalog blend.

Exact sequence, linker status, component ratio, solvent compatibility, stability, sterility, endotoxin, and post-preparation storage require batch-specific analytical and stability documentation. The long-acting DAC study cannot be used as a no-DAC preparation guide.

06Claim audit+

SUPPORTED AT COMPONENT PK/PD LEVELGH-axis response after studied CJC-1295 and Ipamorelin materials

IDENTITY WARNINGWith-DAC and no-DAC records are not interchangeable

NOT ESTABLISHEDLean mass, fat loss, recovery, sleep, skin, or performance outcomes for the exact blend

NOT VALIDATEDCommercial reconstitution, cycling, maximum-protocol, and stacking charts

REFERENCE DESK

All the popular claims—without hiding the gaps.

This retains the detailed topics on Guide references while correcting the common mistake of treating DAC studies as proof for a no-DAC blend.

BENEFITS CLAIM INDEX

Frequently advertised outcomes

COMPONENT PK/PDGrowth-hormone release and selected IGF-I responses after specific studied materials

PRECLINICAL / INDIRECTBone-growth, tissue, and body-composition hypotheses from component or GH-axis research

NOT ESTABLISHED FOR THIS BLENDLean-muscle growth, fat loss, tendon/ligament healing, exercise recovery, collagen/skin changes, anti-aging, better sleep, energy, mood, immune strength, fertility, libido, cardiac repair, pancreatic regeneration, or cognition

SIDE-EFFECT INDEX

What commercial guides report

Injection-site redness/swelling/itching, water retention, bloating, fatigue or lethargy, headache, flushing/heat, tingling, hunger, dizziness, nausea, diarrhea, jitteriness, temporary blood-pressure or pulse changes, hives, or allergic skin reactions.

These reports do not provide reliable incidence rates or establish long-term safety for this exact 5/5 blend.

DAC VERSUS NO DAC

The identity distinction

  • With DAC: albumin-binding, long-acting construct represented by the 2006 human PK/PD record.
  • “No DAC”: commercial name generally used for a shorter GHRH-fragment analog; exact sequence and modification must be verified.
  • Ipamorelin: a separate GHS-R1a agonist with its own PK/PD record.
  • Premixed blend: requires proof for both identities and their ratio; separate studies do not become blend evidence.

CONTRAINDICATION & INTERACTION CLAIMS

No approved complete label exists

Commercial pages advise against use during pregnancy or breastfeeding, with active cancer, untreated cardiovascular disease, hormonal disorders, hypersensitivity, or concurrent GH/secretagogue products.

No controlled interaction study or FDA-approved contraindication list for the exact blend was found. Glucose-regulation, pituitary, endocrine, oncology, and cardiovascular contexts require qualified review rather than a web checklist.

STACKING CLAIMS INDEX

Named on the blend page

L-CarnitineAOD-9604BPC-157TB-500

The site associates these pairings with fatty-acid transport, lipolysis, connective-tissue recovery, and GH-mediated repair. No controlled evidence was found establishing those blend combinations or their safety.

STORAGE & HANDLING

Material-specific records are essential

  • Confirm exact sequence and whether any affinity linker is present.
  • Require separate identity and quantitative evidence for both ingredients.
  • Protect uncharacterized material from uncontrolled heat, light, moisture, and temperature cycling.
  • Do not infer solvent compatibility, concentration, stability, or beyond-use time from a generic peptide guide.
Is no-DAC CJC-1295 the molecule studied in the long-acting human trial?+

Not automatically. The major human CJC-1295 record used a drug-affinity-complex construct. A no-DAC label requires independent identity and evidence.

Does Ipamorelin have human research?+

Yes, a small dose-escalation PK/PD study measured plasma exposure and GH release. That is not the same as proof of muscle, fat-loss, sleep, or recovery benefits.

Is the exact 5 mg + 5 mg blend clinically proven?+

No controlled human efficacy record for this exact premixed catalog blend is indexed here.

Why not use a commercial syringe-unit chart?+

It assumes vial content, two-component ratio, solvent compatibility, final concentration, stability, and a human-use schedule that the component studies do not validate.

REFERENCE LAYERPrimary and authoritative sources shown above control the evidence classification. Reported-practice notes are retained without public vendor attribution.
SEQUENCE CHECK

“No DAC” is not enough.

Confirm the exact peptide sequence, modification pattern, linker status, and nomenclature rather than inferring identity from a short product name.

BLEND CHECK

Two ingredients, two records.

Each component needs identity and quantity evidence. A combined purity result may not answer the ratio or identity of both materials.

TRANSLATION CHECK

PK/PD is not efficacy.

A measured hormone response shows a biological readout within a study. It does not establish a treatment, recovery, body-composition, sleep, or performance benefit.

SOURCE SHELF

Compare exact molecules—not marketing names.